GLP-1 medications have become a major topic in discussions about obesity, weight loss, and overall metabolic health. As more people use these medications to help manage their weight, employers and health plans are facing a growing challenge: how to provide access to potentially valuable treatments while managing the long-term financial impact on healthcare benefits. The issue comes at a time when overweight and obesity remain widespread. According to the World Health Organization (WHO) European Regional Obesity Report 2022, almost 60% of adults in the WHO European Region are overweight or obese, highlighting the scale of the weight-management challenge facing healthcare systems.
At the same time, GLP-1 use among U.S. adults has increased significantly. According to the Gallup National Health and Well-Being Index, 11% of U.S. adults currently report using GLP-1 medications for weight loss, compared with 3% in 2024. Another 15% say they have used the medications for weight loss at some point, an increase of 9 percentage points from 2024.
Table of Contents
- What Are GLP-1 Medications?
- The Growing Impact of GLP-1s on Employer Healthcare Costs
- Why GLP-1 Coverage Has Become an Employer Issue
- Growing Awareness of GLP-1 Medications
- Access Needs to Be Paired With Appropriate Care
- Patient Selection Matters
- Nutrition Support Can Strengthen GLP-1 Programs
- Long-Term Planning Is Essential
- Related FAQs
- When to Call a Professional
- Conclusion
- Key takeaways
What Are GLP-1 Medications?
GLP-1 agonists are medications that help lower blood sugar levels and promote weight loss. There are many different types. And they’re just one part of your treatment plan if you have Type 2 diabetes or obesity. Your healthcare provider can help you decide if they’re right for you.
The Growing Impact of GLP-1s on Employer Healthcare Costs
Employers are already grappling with the challenge of balancing rising healthcare costs with overall workforce wellbeing. Now, the advent of GLP-1 medications, which have shown promising results in managing obesity and related chronic conditions, presents both an opportunity and a challenge. These medications could potentially reduce long-term healthcare expenditures but require a strategic approach to manage their initial high costs and integrate them effectively into employee health benefits. As GLP-1 utilization increases, organizations may need to rethink how wellness, prevention, nutrition, and chronic condition management programs work together.
The question is no longer simply whether GLP-1 medications should be covered. Employers also need to consider how coverage can be structured in a way that supports appropriate treatment while managing long-term costs.
Why GLP-1 Coverage Has Become an Employer Issue
Healthcare benefits are an important part of employee compensation. Workers increasingly expect health plans to provide access to treatments that can help manage chronic conditions and improve quality of life. At the same time, obesity is increasingly recognized as a chronic health condition rather than simply a matter of individual lifestyle choices.
GLP-1 therapies have expanded the treatment options available to eligible patients. For people who have struggled to achieve lasting weight-management results through lifestyle changes alone, these medications may provide another treatment option. For employers, however, adding GLP-1 medications to a health plan requires careful consideration. Companies must evaluate not only the immediate prescription expense but also how ongoing treatment could affect healthcare budgets over time. A Rice University study published in JAMA Network Open found that health insurance costs increased at three times the rate of workers’ earnings between 1999 and 2024. Workers’ contributions toward family health insurance premiums increased by 308%, while total premiums increased by 342%. During the same period, workers’ wages increased by 119%.
Growing Awareness of GLP-1 Medications
GLP-1 awareness has increased alongside utilization. Gallup reported that 91% of U.S. adults are familiar with GLP-1 medications intended for weight loss, compared with 80% in 2024. These findings demonstrate how quickly GLP-1 medications have entered mainstream awareness while also showing that patients are using different types of products.
For employers, greater awareness can translate into greater demand for coverage. As more employees become familiar with these medications, benefits teams may face increasing questions about eligibility, coverage rules, costs, and available support.
Access Needs to Be Paired With Appropriate Care
Providing access to medication without additional support can leave important gaps in a patient’s weight-management journey.
GLP-1 therapy should not be viewed as a replacement for healthy nutrition, physical activity, and other lifestyle measures. Because these medications can influence appetite and food intake, nutritional quality becomes particularly important for people who are eating less than they did previously. This is where multidisciplinary care can add value.
A comprehensive program may connect patients with physicians, registered dietitians, behavioral health professionals, and other qualified providers. Instead of treating medication as the entire solution, employers can support a broader approach that helps employees develop sustainable health behaviors.
Patient Selection Matters
GLP-1 medications are not appropriate for everyone. A responsible coverage strategy should consider medical history, existing conditions, potential contraindications, treatment goals, and an individual’s overall health.
Employees should not be encouraged to pursue these medications simply because they have become popular. Clinical assessment should remain central to treatment decisions.
Employers can support appropriate access by working with healthcare providers and benefits partners to establish evidence-based eligibility criteria. Programs may also include ongoing follow-up to determine whether treatment remains appropriate and whether patients experience adverse effects. This approach can help organizations move beyond a simple choice between unrestricted coverage and complete exclusion.
Nutrition Support Can Strengthen GLP-1 Programs
Nutrition counseling is another important component of comprehensive GLP-1 care. Because these medications can influence appetite and food intake, patients may notice changes in their usual eating patterns. Some may feel full sooner, while others may experience gastrointestinal symptoms or changes in food preferences.
Nutrition professionals can help patients adjust safely. Rather than focusing exclusively on calorie restriction, dietary counseling can emphasize nutrient-dense foods, adequate protein, hydration, meal quality, and sustainable eating habits. For employers, incorporating nutrition support into a GLP-1 benefit could create a more comprehensive approach than prescription coverage alone.
Long-Term Planning Is Essential
Adherence is another important consideration with GLP-1 treatment. The supplied report notes that many patients discontinue treatment within a year without additional lifestyle support.Weight management is rarely a short-term challenge. Some patients may require longer-term treatment, while others may eventually transition to another approach. Employers therefore need to think beyond the initial prescription.
Benefits programs may need clear policies surrounding treatment continuation, clinical reassessment, and follow-up care. They should also account for the possibility that employees may change medications or need additional support to maintain healthy behaviors.
Related FAQs:
Q: How much do GLP-1 drugs cost?
A: Most injectable GLP-1 options can cost up to $500 per month and are offered through manufacturer direct-to-patient programs with a valid prescription. Most commercial insurance plans cover GLP-1s for diabetes management, but fewer cover them for weight management. Medicare currently covers GLP-1s for diabetes, sleep apnea, cardiovascular risk reduction, and MASH.
Q: Why are employers concerned about GLP-1 coverage?
A: The growing use of these medications can create significant pharmacy spending. Employers must balance employee demand and access to treatment with the need to manage healthcare costs and maintain sustainable benefits programs.
Q: Can nutrition support be part of a GLP-1 program?
A: Yes. Nutrition counseling can help patients maintain adequate protein, fiber, fluids, vitamins, and minerals while adapting to changes in appetite and food intake. It can also support sustainable eating habits during and after treatment.
Q: What are the long-term safety risks of GLP-1 drugs?
A: GLP-1s have been used for diabetes treatment since 2005 and for weight management since 2014. To date, long-term studies show sustained benefits and no significant safety concerns, although researchers continue to monitor effects on muscle mass, bone health, and mental well-being as more people use them for longer periods.
When to Call a Professional
Employers may want to evaluate their GLP-1 strategy if:
- Employees are increasingly requesting coverage for weight-management medications
- Prescription spending is becoming difficult to manage
- There is limited nutrition or lifestyle support alongside medication
- Benefits teams lack clear eligibility and continuation criteria
- Employees need additional support with sustainable weight-management behaviors
- The organization wants to evaluate the long-term value of GLP-1 treatment rather than prescription costs alone
Mile High Fitness & Wellness offers nutrition and wellness support that can complement GLP-1 treatment programs. Learn more at Mile High Fitness & Wellness.
Conclusion
GLP-1 medications are rapidly changing the weight-management landscape, and their growing use is creating new challenges for employers and health plans. As GLP-1 therapies continue to influence healthcare benefits, employers may need to move beyond simple prescription coverage and develop more structured programs. The goal should not be to provide medications without appropriate safeguards, nor should it be to prevent eligible employees from accessing potentially valuable treatment. A more balanced approach is to create systems that help appropriate patients receive evidence-based care while giving them the education, nutrition support, and ongoing guidance needed to use treatment responsibly.
Key takeaways:
- GLP-1 use for weight loss among U.S. adults has increased substantially
- Rising utilization can create significant financial considerations for employer health plans
- Medication cost is only one part of the broader healthcare equation
- Appropriate patient selection and clinical oversight are essential
- Nutrition and lifestyle support can strengthen GLP-1 treatment programs
